RaDaR: The Next Ten Years

On Wednesday 28th February 2018 a joint patient and clinician event was held at the Queen Elizabeth Hospital, Birmingham to celebrate RaDaR’s achievements to date and consider where we go in the next ten years.

The Agenda, a report from the day and pdfs of the presentation can be found below.

RaDaR Meeting Agenda

RaDaR Meeting Report

Presentations

RaDaR Introduction – Melanie Dillon

RaDaR Future – Detlef Bockenhauer

Examples of research using RaDaR – Liz Colby

Membranous Nephropathy Presentation Paul Brenchley

Kidney Research UK – Sarah-Louise Harwood & Tracey Murray

Kidney Care UK – Fiona Loud

Expressions of interest for new guidelines

 

We are seeking expressions of interest for Renal Association Members to write new guidelines on the following topics:

  • Medical management of stone disease
  • Pregnancy and renal disease

To apply, please send a statement of no more than one side of A4, explaining why you would like to do this, along with a completed Conflict of Interest Form to Melanie.Dillon@renalregistry.nhs.uk by Tuesday 23rd November.

RaDaR Ethics Amendment Approved

 

The latest RaDaR amendment has now been approved by Ethics. The main changes concern clarification that RaDaR consent covers Patient View Sign-up, subject to local availability, and that patients consent to being contacted directly by a member of the central RaDaR team and/or their Rare Disease Group Lead regarding information events or further research studies.

The amendment also allows for data linkage to other registries, including the Hospital Episode Statistics (HES) and Office for National Statistics (ONS) databases. This will enable a far more comprehensive RaDaR data-set than is currently available with manual data entry. It will also allow for longitudinal follow-up of patients who have previously consented to condition-specific research studies, or who do so in the future.

Copies of the new documents have been sent to all current sites and are also available from the Criteria and Consent page.

If you have any queries about the amendment please contact Melanie.Dillon@RenalRegistry.nhs.uk

RaDaR Ethics amendment submitted

Following a review of our revised consent documents by NHS Digital, we have just submitted the latest RaDaR amendment to the South West – Central Bristol Research Ethics Committee.

The main changes concern clarification that RaDaR consent covers Patient View Sign-up, subject to local availability, and that patients consent to being contacted directly by a member of the central RaDaR team and/or their Rare Disease Group Lead regarding information events or further research studies.

The amendment will also allow for data linkage to other registries, including the Hospital Episode Statistics (HES) and Office for National Statistics (ONS) databases. This will allow for a far more comprehensive RaDaR data-set than is currently available with manual data entry. It will also allow for longitudinal follow-up of patients who have previously consented to condition-specific research studies, or who do so in the future.

No action is required on behalf of the sites at present. We will everyone informed as to the progress of this amendment and let you know when it is approved.

If you have any queries about the amendment please contact Melanie.Dillon@RenalRegistry.nhs.uk

Primary Hyperoxaluria Webinar, 15th August

 

 

The Oxalosis & Hyperoxaluria Foundation (OHF) and Dicerna Pharmaceuticals invite you to participate in a webinar on Tuesday, August 15, 2017 at 16.00 hours GMT to discuss research presented by Dicerna during the 12th International Workshop on Primary Hyperoxaluria in Tenerife, Spain in July.

At the meeting, Dicerna announced the expansion of its drug development programs to encompass all forms of primary hyperoxaluria (PH). Based on new pre-clinical data presented in Tenerife, the investigational therapy DCR-PHXC has the potential to treat all forms of PH.

The webinar will provide an overview of the following research topics:

• The need for new treatment strategies for all types of PH
• The role of the LDHA gene in the pathogenesis of PH
• The DCR-PHXC preclinical data demonstrate potent, durable, and precise knockdown of LDHA in animal models of PH1, PH2 and idiopathic PH, and show a simple, direct linear relationship between LDHA inhibition and oxalate production
• Clinical development plans and timelines for DCR-PHXC

Speakers

• Kim Hollander, Executive Director, Oxalosis & Hyperoxaluria Foundation

• Dr Sally-Anne Hulton, M.D. Paediatric Nephrology, Birmingham Children’s Hospital UK

• Ralf Rosskamp, M.D. Chief Medical Officer, Dicerna Pharmaceuticals

Participate

Questions

Ask a question by emailing: julieb@ohf.org (subject line: Dicerna Webinar) by Sunday, August 13, 2017.